Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A
LUNG-MAP Treatment Trial)
How well does the drug, selpercatinib, works in treating patients with RET fusion-positive
non-small cell lung cancer that is stage IV or has come back (recurrent)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating
patients with RET fusion-positive non-small cell lung cancer that is stage IV or has
come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.
Study Reference #: CLUN20016
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search